Clinical Research Directory

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

Sponsor: University of Michigan Rogel Cancer Center

Summary

This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.

Official title: UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)

Key Details

Conditions

Interventions

Locations (1)